Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:alsoKnownAs |
plitidepsin
|
| gptkbp:approvedBy |
gptkb:Australia
|
| gptkbp:CASNumber |
300801-71-2
|
| gptkbp:chemicalClass |
depsipeptide
|
| gptkbp:clinicalTrialPhase |
phase III
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:PharmaMar
|
| gptkbp:hasMolecularFormula |
C57H87N7O15
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aplidin
|
| gptkbp:investigatedBy |
gptkb:COVID-19
|
| gptkbp:mechanismOfAction |
inhibits eEF1A protein
|
| gptkbp:origin |
marine tunicate Aplidium albicans
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting fatigue neutropenia myalgia |
| gptkbp:usedFor |
multiple myeloma
|
| gptkbp:bfsParent |
gptkb:PharmaMar
|
| gptkbp:bfsLayer |
7
|